- Home
- ATAI vs ALLO Comparison
ATAI vs ALLO Comparison
Compare ATAI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ALLO
- Stock Information
- Founded
- ATAI 2018
- ALLO 2017
- Country
- ATAI Germany
- ALLO United States
- Employees
- ATAI N/A
- ALLO N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAI Health Care
- ALLO Health Care
- Exchange
- ATAI Nasdaq
- ALLO Nasdaq
- Market Cap
- ATAI 444.7M
- ALLO 363.1M
- IPO Year
- ATAI 2021
- ALLO 2018
- Fundamental
- Price
- ATAI $3.76
- ALLO $1.30
- Analyst Decision
- ATAI Strong Buy
- ALLO Strong Buy
- Analyst Count
- ATAI 3
- ALLO 9
- Target Price
- ATAI $13.33
- ALLO $8.44
- AVG Volume (30 Days)
- ATAI 6.6M
- ALLO 3.6M
- Earning Date
- ATAI 08-12-2025
- ALLO 08-06-2025
- Dividend Yield
- ATAI N/A
- ALLO N/A
- EPS Growth
- ATAI N/A
- ALLO N/A
- EPS
- ATAI N/A
- ALLO N/A
- Revenue
- ATAI $1,863,000.00
- ALLO N/A
- Revenue This Year
- ATAI $423.05
- ALLO N/A
- Revenue Next Year
- ATAI N/A
- ALLO $199.63
- P/E Ratio
- ATAI N/A
- ALLO N/A
- Revenue Growth
- ATAI 572.56
- ALLO N/A
- 52 Week Low
- ATAI $1.03
- ALLO $0.86
- 52 Week High
- ATAI $4.00
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- ATAI 69.83
- ALLO 45.12
- Support Level
- ATAI $3.06
- ALLO $1.21
- Resistance Level
- ATAI $3.70
- ALLO $1.50
- Average True Range (ATR)
- ATAI 0.28
- ALLO 0.11
- MACD
- ATAI 0.03
- ALLO -0.00
- Stochastic Oscillator
- ATAI 89.08
- ALLO 9.37
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.